Hybrid Approach Improves Success of Chronic Total Occlusion Angioplasty
Overview
Authors
Affiliations
Objectives: Treatment options for coronary chronic total occlusions (CTO) are limited, with low historical success rates from percutaneous coronary intervention (PCI). We report procedural outcomes of CTO PCI from 7 centres with dedicated CTO operators trained in hybrid approaches comprising antegrade/retrograde wire escalation (AWE/RWE) and dissection re-entry (ADR/RDR) techniques.
Methods: Clinical and procedural data were collected from consecutive unselected patients with CTO between 2012 and 2014. Lesion complexity was graded by the Multicentre CTO Registry of Japan (J-CTO) score, with ≥2 defined as complex. Success was defined as thrombolysis in myocardial infarction 3 flow with <30% residual stenosis, subclassified as at first attempt or overall. Inhospital complications and 30-day major adverse cardiovascular events (MACEs, death/myocardial infarction/unplanned target vessel revascularisation) were recorded.
Results: 1156 patients were included. Despite high complexity (mean J-CTO score 2.5±1.3), success rates were 79% (first attempt) and 90% (overall) with 30-day MACE of 1.6%. AWE was highly effective in less complex lesions (J-CTO ≤1 94% success vs 79% in J-CTO score ≥2). ADR/RDR was used more commonly in complex lesions (J-CTO≤1 15% vs J-CTO ≥2 56%). Need for multiple approaches during each attempt increased with lesion complexity (17% J-CTO ≤1 vs 48% J-CTO ≥2). Lesion modification ('investment procedures') at the end of unsuccessful first attempts increased the chance of subsequent success (96% vs 71%).
Conclusions: Hybrid-trained operators can achieve overall success rates of 90% in real world practice with acceptable MACE. Use of dissection re-entry and investment procedures maintains high success rates in complex lesions. The hybrid approach represents a significant advance in CTO treatment.
Zheng N, Ai H, Zhao Y, Li H, Yang G, Tang G Aging Med (Milton). 2024; 7(4):463-471.
PMID: 39234198 PMC: 11369334. DOI: 10.1002/agm2.12350.
Cheng J, Lee C, Chiang J, Liu S, Huang C, Liou J Int J Obes (Lond). 2024; 48(12):1767-1774.
PMID: 39232101 PMC: 11584385. DOI: 10.1038/s41366-024-01623-2.
Chakravartti J, Feser W, Plomondon M, Valle J, Rao S, Gutierrez J J Soc Cardiovasc Angiogr Interv. 2024; 1(6):100440.
PMID: 39132361 PMC: 11308032. DOI: 10.1016/j.jscai.2022.100440.
Sidik N, McEntegart M, Joshi F, Owens C, Shaukat A, Gallagher S J Soc Cardiovasc Angiogr Interv. 2024; 3(7):102017.
PMID: 39132006 PMC: 11308310. DOI: 10.1016/j.jscai.2024.102017.
Zhang T, Zhang Y, Feng T, Zhao L J Thorac Dis. 2024; 16(5):3272-3281.
PMID: 38883647 PMC: 11170411. DOI: 10.21037/jtd-24-610.